Sumatriptan (50 mg tablets vs. 25 mg suppositories) in the acute treatment of menstrually related migraine and oral contraceptive-induced menstrual migraine: a pilot study

Autor:	Chiara Benedetto, Gianni Allais, Fabio Facchinetti, Andrea R. Genazzani, Gian Carlo Di Renzo, Maurizio Roncolato, Rossella E. Nappi, Ilaria Castagnoli Gabellari, Manuela Bellafronte
Rok vydání:	2010
Předmět:	Adult Migraine without Aura Nausea Endocrinology Diabetes and Metabolism Administration Oral Pilot Projects Suppository menstrual migraine Young Adult Endocrinology Administration Rectal Acute treatment oral contraceptives sumatriptan medicine Humans Menstrual Cycle Sumatriptan acute treatment of menstrually migraine oral contraceptive-induced menstrual migraine Cross-Over Studies business.industry Suppositories Obstetrics and Gynecology Middle Aged Serotonin 5-HT1 Receptor Agonists medicine.disease Crossover study Phonophobia Migraine Tolerability Anesthesia Vomiting Female medicine.symptom business Contraceptives Oral medicine.drug
Zdroj:	Gynecological Endocrinology. 26:773-779
ISSN:	1473-0766 0951-3590
DOI:	10.3109/09513590.2010.487607
Popis:	Migraine attacks are common in the perimenstrual period (menstrually-related migraine, MRM) and can be particularly exacerbated by the cyclic suspension of oral contraceptives (oral contraceptive-induced menstrual migraine, OCMM). This cross-over, randomised study evaluated the efficacy and tolerability of rectal (25 mg) and oral (50 mg) sumatriptan in the treatment of 232 menstrual migraine attacks (135 MRM and 97 OCMM). Two hours after suppository administration, 72% of patients in the MRM group achieved pain relief and 24% were pain free; after tablet administration, the percentages were 66% and 27%, respectively. In the OCMM group 55% of patients improved at 2 h with suppositories and 46% with tablets, 27% of patients were pain-free after suppositories and 18% after tablets. Fifty percent of patients given suppositories were pain-free at 4 h post-treatment and 47% of those given tablets. Sumatriptan also effectively alleviated symptoms associated with migraine, such as nausea, vomiting and photo/phonophobia. A single dose of medication sufficed for pain relief without relapse in 47.4% of the attacks (MRM: 66%; OCMM: 33%). Both formulations were well tolerated.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::130939bf55bff041e6e93fa6e5b0cf6c https://doi.org/10.3109/09513590.2010.487607 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.